Skip to main content

Our mission

We create inspired medicines that matter to cancer patients based on our expertise and ADC technologies

Our ADC technology platforms

In our technology platforms, we use a variety of different payloads to research, manufacture and clinically develop highly effective ADCs for the treatment of a variety of malignant hematological and solid tumors. ADCs combine the high affinity and specificity of antibodies with the potency of small toxic molecules to fight cancer.

With our unique expertise in the active ingredient Amanitin from the green death cap mushroom, we have developed a patented and proprietary ATAC technology. The toxin's unique mode of action offers the opportunity to break through drug resistance and eliminate even quiescent tumor cells, which could lead to significant advances in cancer therapy – even for patients who no longer respond to any other treatment.

News

PR: Heidelberg Pharma Announces First Patient Dosed in Phase I Study of Amanitin-based ADC Candidate HDP-102 for Non-Hodgkin Lymphoma
27 May 2025
Open
PR: Heidelberg Pharma Reports on the Results of the Ordinary Annual General Meeting 2025 and New Supervisory Board
15 May 2025
Open
PR: Heidelberg Pharma to Present Promising New Clinical Data on its Lead ATAC Candidate HDP-101 at EHA 2025
14 May 2025
Open
PR: Heidelberg Pharma AG: Interim Statement on the First Three Months of Financial Year 2025
24 April 2025
Open

Meet us

EHA Annual Congress

12. - 15. Juni

Webinar: Pioneering New Treatment Options in Relapsed or Refractory Multiple Myeloma with a New Amanitin-based ADC

17. Juni, 5 pm CEST

ADC Toxicity Summit

8. - 10. Juli

ADC Linker & Conjugation Summit

19. - 21. August

HIT - Hamburger Investoren Tage

27. - 28. August

    Partner Information

    TitleDate
    Telix: FDA Accepts BLA for TLX250-CDx (Zircaix®) for Kidney Cancer Imaging, Grants Priority Review
    26 February 2025
    Read more
    Telix: Telix Files TLX250-CDx (Zircaix®) BLA for Kidney Cancer Imaging
    30 December 2024
    Read more
    Telix: First Patient Dosed in Phase III ZIRCON-CP Trial of TLX250-CDx for Kidney Cancer Imaging in Chinese Patients
    28 November 2024
    Read more
    Telix: First Patient Dosed in Phase II ‘CA-NINE’ Trial of TLX250-CDx for Detection of Recurrent Kidney Cancer After Surgery
    3 October 2024
    Read more